UBS initiated coverage of Loblaw (LBLCF) with a Buy rating and C$225 price target The firm believes the company commands 27% market share of the Canadian food and drug retail market. This is meaningfully higher than Loblaw’s next largest peer, giving it a scale advantage as it looks to build on its edge in the market, contends UBS.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.